Medtronic Shares First Results from New Symplicity Spyral RDN Study
Medtronic announced the first results from the high cardiovascular risk cohort of its SPYRAL AFFIRM study, showcasing significant and sustained blood pressure reductions with its Symplicity Spyral renal denervation (RDN) system.
The study, which completed enrollment, reported data from 210 patients across 59 sites in Europe, Australia, and the U.S., with no increase in anti-hypertensive medication use at six months.
The findings were presented at the 2025 Transcatheter Cardiovascular Therapeutics (TCT) conference in San Francisco, adding to the three-year Symplicity Spyral outcomes shared at TCT.
Significant, safe and sustained blood pressure reductions with the RDN system.
Author's summary: Medtronic's Symplicity Spyral RDN system shows promising results.